New centers on therapeutics look at real-life drug use

Article

Since 2000, there have been several types of warnings about the drug Remicade (infliximab), a biological therapeutic product indicated for rheumatoid arthritis and Crohn's disease. Tuberculosis and other opportunistic infections have been reported in clinical research and elsewhere. The manufacturer has warned that patients should be given a TB skin test, and that treatment for any latent TB infection should be started before infliximab use.

Recent Videos
Related Content
Q&A: Factors Showing Tirzepatide is More Beneficial Than Semaglutide | ASHP Midyear

Q&A: Factors Showing Tirzepatide is More Beneficial Than Semaglutide | ASHP Midyear

Brian Nowosielski;Jennifer Clements, PharmD, BCACP, BC-ADM, BCPS, CDCES, FADCES, FCCP;Ashley Gallagher
January 7th 2025
Article

Jennifer Clements, PharmD, BCACP, BC-ADM, BCPS, CDCES, FADCES, FCCP, discussed the benefits of tirzepatide compared with semaglutide.

pharmacist and patient

Reach Your Business Goals in 2021

Jennifer Barrett
March 25th 2021
Podcast

In part 1 of our podcast series with American Associated Pharmacies (AAP), AAP President and CEO Jon Copeland dives into key pharmacy industry trends.

Examining Impact of Continuous Glucose Monitors on Diabetes | ASHP Midyear

Examining Impact of Continuous Glucose Monitors on Diabetes | ASHP Midyear

Killian Meara
December 16th 2024
Article

Two posters presented at the meeting looked into the topic CGMs in diabetes care.

Over the Counter podcast

ThoughtSpot Series: Closing the Healthcare Gap

January 7th 2021
Podcast

Our final episode in our ThoughtSpot 2020 podcast series features NPhA president Dr. Ryan Marable and immediate past president Dr. Lakesha Butler, who share insights on health disparities and the social determinants of health.

Q&A: Educating Patients, Providers to Increase Biosimilar Implementation | ASHP Midyear

Q&A: Educating Patients, Providers to Increase Biosimilar Implementation | ASHP Midyear

Brian Nowosielski;Amanuel Y. Kehasse, PharmD, PhD;Ashley Gallagher
December 16th 2024
Article

Drug Topics met with Amanuel Kehasse, PharmD, PhD, to discuss the barriers surrounding biosimilar implementation in the prescription drug market.

Q&A: Pharmacists’ Understanding of CKD Therapies, Adverse Effects | ASHP Midyear

Q&A: Pharmacists’ Understanding of CKD Therapies, Adverse Effects | ASHP Midyear

Brian Nowosielski;Denise Kelley, PharmD, BCPS, FASHP ;Ashley Gallagher
December 13th 2024
Article

Denise Kelley, PharmD, BCPS, FASHP, joined Drug Topics to discuss various medications for chronic kidney disease and their common adverse reactions.

© 2025 MJH Life Sciences

All rights reserved.